{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:05:55Z","timestamp":1759032355314},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T00:00:00Z","timestamp":1097020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To examine the antiparkinsonian effects of blocking glycine<jats:sub>B<\/jats:sub> receptors, we designed a pilot study testing the potent and selective antagonist, PAMQX, in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated primates. PAMQX had no intrinsic effects but markedly potentiated the antiparkinsonian action of levodopa. In a dose\u2010dependent fashion, coadministration of the glycine<jats:sub>B<\/jats:sub> antagonist with levodopa extended the response duration by nearly 60%. It is noteworthy that PAMQX, within a considerable dose range, did not cause ataxia or other side effects. These data indicate that blocking <jats:italic>N<\/jats:italic>\u2010methyl\u2010<jats:sc>D<\/jats:sc>\u2010aspartate receptors selectively to manipulate dopaminergic\u2010mediated motor responses may be produced effectively by glycine<jats:sub>B<\/jats:sub> antagonists. Ann Neurol 2004<\/jats:p>","DOI":"10.1002\/ana.20279","type":"journal-article","created":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T20:03:44Z","timestamp":1097093024000},"page":"723-727","source":"Crossref","is-referenced-by-count":13,"title":["Prolongation of levodopa responses by glycine<sub>B<\/sub> antagonists in parkinsonian primates"],"prefix":"10.1002","volume":"56","author":[{"given":"Stella M.","family":"Papa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves P.","family":"Auberson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Timothy","family":"Greenamyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01258633"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280411"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350605"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390505"},{"key":"e_1_2_6_6_2","first-page":"1034","article-title":"Differing effects of N\u2010methyl\u2010D\u2010aspartate receptor subtype selective antagonists on dyskinesias in levodopa\u2010treated 1\u2010methyl\u20104\u2010phenyl\u2010tetrahydropyridine monkeys","volume":"290","author":"Blanchet PJ","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7374"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7444"},{"key":"e_1_2_6_9_2","first-page":"597","article-title":"Glycine and N\u2010methyl\u2010D\u2010aspartate receptors: physiological significance and possible therapeutic applications","volume":"50","author":"Danysz W","year":"1998","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01451-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00720-3"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00576-4"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90176-G"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00924-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.6031"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature715"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246054"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00165-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13556.x"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.20279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.20279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:11:35Z","timestamp":1696950695000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.20279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,6]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1002\/ana.20279"],"URL":"https:\/\/doi.org\/10.1002\/ana.20279","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,6]]}}}